---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-055322"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T02:43:51.998158+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Verastem reports 83% ORR in RAMP 205 PDAC trial; details VS-7375 KRAS G12D inhibitor

## Summary
- FDA approved avutometinib + defactinib (AVMAPKI/FAKZYNJA) on May 8, 2025 for KRAS-mutated recurrent LGSOC.
- RAMP 205 Phase 1/2 in first-line mPDAC: 83% unconfirmed ORR (10/12) at dose level 1; all patients had tumor shrinkage.
- RP2D set: avutometinib 2.4mg, defactinib 200mg, gemcitabine 800mg/m2, nab-paclitaxel 125mg/m2.
- VS-7375: oral KRAS G12D ON/OFF inhibitor with potent preclinical selectivity and activity; Phase 1/2a trial planned.
- Preliminary data suggest patients may exceed historical median PFS for gemcitabine/nab-paclitaxel.

## SEC filing metadata
- accession: 0001104659-25-055322
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465925055322/0001104659-25-055322-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465925055322/tm2516844d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-055322
- JSON: https://secwatch.observer/filing/0001104659-25-055322.json
- Plain text: https://secwatch.observer/filing/0001104659-25-055322.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.